-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, V+cujDH/9poRdBR5ZhuVSC6rGSqkrO7GYZuGNRraqPA81IWnO5+QS2szq9hOEy75 Y2pJ1BHbHdbI5mDlB1Guhg== 0001104659-03-013093.txt : 20030626 0001104659-03-013093.hdr.sgml : 20030626 20030626092512 ACCESSION NUMBER: 0001104659-03-013093 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20030623 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20030626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 03757543 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 8-K 1 j2443_8k.htm 8-K

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

CURRENT REPORT

 

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): June 23, 2003

 

Savient Pharmaceuticals, Inc.

(Exact name of issuer as specified in its charter)

 

 

 

Delaware

 

0-15313

 

13-3033811

(State or Other Jurisdiction

 

(Commission File Number)

 

(IRS Employer

of Incorporation)

 

 

 

Identification No.)

 

 

 

 

 

One Tower Center, 14th Floor, East Brunswick, New Jersey

08816

(Address of Principal Executive Offices)

 

(Zip Code)

 

 

 

 

 

Registrant’s telephone number, including area code: (732) 418-9300

 

Bio-Technology General Corp.

(Former Name or Former Address, if Changed Since Last Report.)

 

 

 

ITEM 9.     REGULATION FD DISCLOSURE.

 

                On June 23, 2003, Sim Fass, Chairman and Chief Executive Officer of Savient Pharmaceuticals, Inc., in various meetings held with investors following his opening of NASDAQ that day to mark the change of the name of the company from Bio-Technology General Corp. to Savient Pharmaceuticals, Inc., in response to questions, communicated the following:

 

The conversion of the 2.5 mg-based Oxandrin® prescriptions to 10 mg—based prescriptions is continuing and at the end of May, approximately 26% of all Oxandrin prescriptions were 10 mg—based.

 

Approval of a new manufacturing site for Delatestryl®, which, as previously disclosed, is SABEX in Canada, may possibly occur by year-end.  Delatestryl sales for 2003 are currently projected to be approximately $9 million based on previously manufactured inventory.

 

The receptor to which the Company’s anti-leukemic monoclonal antibody, BTG-271, binds has been identified as CD-162.  This receptor is sulfated on leukemic cells but is not sulfated on normal cells.  BTG-271 appears to recognize only the modified receptor.

 

The Company received an informal request for documents from a regional office of the S.E.C. relating to the restatement last year of the Company’s financials for the years 1999, 2000, 2001 and the first half of 2002. The Company is providing requested materials.

 

2

 

SIGNATURES

 

 

         Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

SAVIENT PHARMACEUTICALS, INC.

 

 

 

 

 

(Registrant)

 

 

 

 

 

 

 

 

 

 

 

 

By:

 /s/ Whitney K. Stearns, Jr.

 

 

 

 

 

 

Whitney K. Stearns, Jr.

 

 

 

 

 

 

Senior Vice President-Chief Financial Officer and

 

 

 

 

 

Treasurer

 

 

 

Dated: June 26, 2003

 

3

 -----END PRIVACY-ENHANCED MESSAGE-----